Intravenous 6‐mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group study CCG 1922

To compare outcomes of patients with NCI standard risk acute lymphoblastic leukemia (ALL) who relapsed after being randomized to receive either oral or intravenous 6‐mercaptopurine (6MP) in the Children's Cancer Group study CCG 1922.

[1]  N. Heerema,et al.  Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. , 2003, Blood.

[2]  M. Relling,et al.  De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. , 2002, Blood.

[3]  N. Schmitz,et al.  Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. , 2002, Blood.

[4]  W. Evans.  Thiopurine S-methyltransferase: a genetic polymorphism that affects a small number of drugs in a big way. , 2002, Pharmacogenetics.

[5]  D. Campana,et al.  Childhood acute lymphoblastic leukaemia--current status and future perspectives. , 2001, The Lancet. Oncology.

[6]  R. Gelber,et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. , 2001, Blood.

[7]  A. Bleyer,et al.  Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. , 1998, Blood.

[8]  P. Steinherz,et al.  Survival after relapse in childhood acute lymphoblastic leukemia , 1998, Cancer.

[9]  T. Salmi,et al.  Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO). , 1997, Journal of pediatric hematology/oncology.

[10]  Qinguo Zheng,et al.  Role of Postreplicative DNA Mismatch Repair in the Cytotoxic Action of Thioguanine , 1996, Science.

[11]  D. Campana,et al.  Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  W. Kamps,et al.  High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  B. Camitta,et al.  Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Lilleyman,et al.  Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia , 1994, The Lancet.

[15]  D. Pinkel.  Intravenous mercaptopurine: life begins at 40. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  B. Bostrom,et al.  Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. , 1993, The American journal of pediatric hematology/oncology.

[17]  R. Pieters,et al.  Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia , 1991, The Lancet.

[18]  J. Lilleyman,et al.  Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Shuster,et al.  Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Weinshilboum,et al.  Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism , 1989, Clinical pharmacology and therapeutics.

[21]  G. Chrousos,et al.  Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Riccardi,et al.  Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? , 1983, The New England journal of medicine.

[23]  R. Weinshilboum,et al.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. , 1980, American journal of human genetics.

[24]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[25]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[26]  H. McLeod,et al.  The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics. , 2002, Pharmacogenomics.

[27]  A. Hall,et al.  Expression of DNA mismatch repair proteins in acute lymphoblastic leukaemia and normal bone marrow. , 1999, Advances in experimental medicine and biology.

[28]  C. Pui,et al.  Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Shuster,et al.  Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. , 1991, Medical and pediatric oncology.

[30]  E. Thompson,et al.  Steroid hormone actions in tissue culture cells and cell hybrids--their relation to human malignancies. , 1976, Recent progress in hormone research.